- The Adverse Adverse Events Following Immunisation (AEFI) analysis of 63 million vaccinations suggested that the Sinovac vaccine has an overall good safety profile amongst the child population.
- DG Hisham announced that the Drug Control Authority (DCA) has approved the use of the Sinovac Covid-19 vaccine for children and adolescents.
Sinovac Vaccine Approved And Safe For Use In Children Says Pharmaniaga
Currently, the process of administering vaccines to school-going children is rapidly ongoing to ensure that they are fully protected against Covid-19 before face-to-face classes start. especially with the presence of the highly transmissible Delta variant.
Now, the Sinovac Covid-19 vaccine is going to be used on children and medical authorities are assuring parents that it is safe. With more than 63 million doses administered to the population aged 12 to 17 years in China, it’s no doubt effective to protect children and adolescents from the virus.
In a statement by Pharmaniaga Bhd, the Adverse Adverse Events Following Immunisation (AEFI) analysis of 63 million vaccinations suggested that the Sinovac vaccine has an overall good safety profile amongst the child population. Furthermore, the data collected were mainly routine injection site events with normal symptoms.
Adding on to this is Health director-general Tan Sri Dr Noor Hisham Abdullah who announced that the Drug Control Authority (DCA) has approved the use of the Sinovac Covid-19 vaccine for children and adolescents.
The Pharmaniaga Bhd group managing director, Datuk Zulkarnain Md Eusope said the vaccine has been widely administered to the younger population aged 12 to 17 years in China and to date, there is no record on any safety risk information of AEFI related to the vaccination.
Image Source: The Straits Times
The vaccine will also be made available at selected private hospitals and clinics very soon as an option for parents. As for the symptoms, fret not, because the normal symptoms include dizziness and nausea, which are very mild.
Furthermore, Pharmaniaga Bhd said, “The Sinovac COVID-19 vaccine is developed using inactivated virus which is a well-established technology of more than 40 years that is also being used commonly in many types of vaccine currently available in the market including for polio, Hepatitis A and rabies."
For some background information, last Friday, Dr Noor Hisham said the Sinovac COVID-19 vaccine for adolescents aged 12 and above was allowed as agreed at the 364th Meeting of the DCA.